Hodgkin's disease in the setting of human immunodeficiency virus infection

Scandinavian Journal of Infectious Diseases

Volumn 35, Issue 2, 2003, Pages 136-141

  Calza, Leonardo ^a   Manfredi, Roberto ^a   Colangeli, Vincenzo ^a   Dentale, Nicola ^a   Chiodo, Francesco ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDINAVIR; LAMIVUDINE; STAVUDINE; VINBLASTINE;

ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DEATH; DISEASE COURSE; FEMALE; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; PATIENT REFERRAL; POPULATION RESEARCH; RETROSPECTIVE STUDY; RISK ASSESSMENT; TREATMENT OUTCOME;

ADULT; AGE DISTRIBUTION; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COMBINED MODALITY THERAPY; COMORBIDITY; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; INCIDENCE; ITALY; LYMPHOMA, AIDS-RELATED; MALE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0037237807     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/0036554021000026994     Document Type: Article

References (37)

1. Goedert JJ, Coté TR, Virgo P, Scoppa SM, Kingma DW, Gail MH, et al. Spectrum of AIDS-associated malignant disorder. Lancet 1998; 351: 1833-9.
2. Centers for Disease Control. Classification system for human T-lymphotropic virus type III/lymphoadenopathy-associated virus infections. MMWR Morb Mortal Wkly Rep 1986; 35: 334-9.
3. Levine AM. HIV-associated Hodgkin's disease. Biologic and clinical aspects. Hematol Oncol Clin North Am 1996; 10: 1135-48.
4. Levine AM. Hodgkin's disease in the setting of human immunodeficiency virus infection. Monogr Natl Cancer Inst 1998; 23: 37-42.
5. Palella Jr FJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-60.
6. Ledergerber B, Telenti A, Effer M. Risk of HIV-related Kaposi's sarcoma and non-Hodgkin's lymphoma with potent antiretroviral therapy: prospective cohort study. Br Med J 1999; 319: 23-4.
7. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's disease. N Engl J Med 1998; 339: 1506-14.
8. Davis S, Dahlberg S, Myers MH, Chen A, Steihnorm SC. Hodgkin's disease in the United States: a comparison of patient characteristics and survival in the centralized cancer patient data system and the surveillance, epidemiology, and results program. J Natl Cancer Inst 1987; 78: 471-8.
9. Marafioti T, Hummel M, Anagnostopoulos I, Foss HD, Falini B, Delsol G, et al. Origin of nodular lymphocyte-predominant variant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N Engl J Med 1997; 337: 453-8.
10. Ohno T, Stribley JA, Wu G, Hinrichs SH, Weisenburger DD, Chan WC. Clonality in nodular lymphocyte-predominant Hodgkin's disease. N Engl J Med 1997; 337: 459-65.
11. Marafioti T, Hummel M, Foss HD, Laumen H, Korbjuhn P, Anagnostopoulos I, et al. Hodgkin's disease and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95: 1443-50.
12. Caussinus E, Meggetto F, Delsol G, Brousset P. Simultaneous occurrence of Epstein-Barr virus associated Hodgkin's disease and HHV-8 related multicentric Castleman's disease: a fortuitous event? J Clin Pathol 2001; 54: 790-1.
13. Audouin J, Diebold J, Pallesen G. Frequent expression of Epstein-Barr virus latent membrane protein-1 in tumour cells of Hodgkin's disease in HIV-positive patients. J Pathol 1992; 167: 381-4.
14. Ambinder RF. Epstein-Barr virus associated lymphoproliferations in the AIDS setting. Eur J Cancer 2001; 37: 1209-16.
15. Tirelli U, Spina M, Gaidano G, Vaccher E, Franceschi S, Carbone A. Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. AIDS 2000; 14: 1675-88.
16. Hessol NA, Katz MH, Liu JY, Buchbinder SP, Rubino CJ, Holmberg SD. Increased incidence of Hodgkin's disease in homosexual men with HIV infection. Ann Intern Med 1992; 117: 309-11.
17. Grulich AE, Wan X, Law MG, Coates M, Kaldor JM. Risk of cancer in people with AIDS. AIDS 1999; 13: 839-43.
18. Reynolds P, Saunders LD, Layefsky ME, Lemp GF. The spectrum of acquired immunodeficiency syndrome (AIDS)-associated malignancies in San Francisco, 1980-1987. Am J Epidemiol 1993; 137: 19-30.
19. Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994; 86: 1711-6.
20. Franceschi S, Dal Maso L, Arniani S, Crosignani P, Vercelli M, Simonato L, et al. for the Cancer and AIDS Registry Linkage Study. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Br J Cancer 1998; 78: 966-70.
21. Grulich AE, Li Y, McDonald A, Correll PKL, Law MG, Kaldor JM. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS 2002; 16: 1155-61.
22. Rapezzi D, Ugolini D, Ferraris AM, Racchi O, Gaetani GF. Histological subtypes of Hodgkin's disease in the setting of HIV infection. Ann Hematol 2001; 80: 340-4.
23. Uccini S, Monardo F, Stoppacciaro A, Gradilone A, Agliano AM, Faggioni A, et al. High frequency of Epstein-Barr virus genome detection in Hodgkin's disease of HIV-positive patients. Int J Cancer 1990; 46: 581-5.
24. Dolcetti R, Zancai P, De Re V, Gloghini A, Bigoni B, Pivetta B, et al. Epstein-Barr virus strains with latent membrane protein-1 deletions: prevalence in the Italian population and high association with human immunodeficiency virus-related Hodgkin's disease. Blood 1997; 89: 1723-31.
25. Tsimberidou AM, Sarris AH, Medeiros LJ, Mesina O, Rodriguez MA, Hagemeiste FB, et al. Hodgkin's disease in patients infected with human immunodeficiency virus: frequency, presentation and clinical outcome. Leuk Lymphoma 2001; 41: 535-44.
26. Poluri A, Shan KG, Carew JF, Shana AR, Har-El G, Lucente FE, Singh B. Hodgkin's disease of the head and neck in human immunodeficiency virus-infected patients. Am J Otolaryngol 2002; 23: 12-6.
27. Levine AM, Scadden DT, Zaia JA, Krishnan A. Hematologic aspects of HIV/AIDS, Hematology 2001; 463-478.
28. Lyter DW, Bryant J, Thackeray R, Rinaldo CR, Kingsley LA. Incidence of human immunodeficiency virus-related and nonrelated malignancies in a large cohort of homosexual men. J Clin Oncol 1995; 13: 2540-6.
29. Levine AM, Li P, Cheung T, Tulpule A, Von Roenn J, Nathwani BN, Ratner L. Chemotherapy consisting of DTIC with G-CSF in HIV-infected patients with newly diagnosed Hodgkin's disease: a prospective, multi-institutional AIDS Clinical Trials Group Study (ACTG 149). J Acquir Immune Defic Syndr 2000; 24: 444-50.
30. Re A, Casari S, Cattaneo C, Facchetti F, Cadeo G, Carosi G, Rossi G. Hodgkin disease in patients infected by human immunodeficiency virus results in clinical features and a prognosis similar to those in patients with human immunodeficiency virus-related non-Hodgkin lymphoma. Cancer 2001; 92: 2739-45.
31. Errante D, Gabarre J, Ridolfo AL, Rossi G, Nosari AM, Gisselbrecht C, et al. Hodgkin's disease in 35 patients with HIV infection: an experience with epirubicin, bleomycin, vinblastine and prednisone chemotherapy in combination with antiretroviral therapy and primary use of G-CSF. Ann Oncol 1999; 10: 189-95.
32. Spina M, Sandri S, Tirelli U. Hodgkin's disease in HIV-infected individuals. Curr Opin Oncol 1999; 11: 522-6.
33. Cossman J, Annunziata CM, Barash S, Staudt L, Dillon P, He WW, et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 1999; 94: 411-6.
34. Foss HD, Reusch R, Demel G, Lenz G, Anagnostopoulos I, Hummel M, Stein H. Frequent expression of the B-cell specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999; 94: 3108-13.
35. Spina M, Gabarre J, Fasan M. Stanford V regimen and concomitant highly active antiretroviral therapy is feasible and active in patients with Hodgkin's disease and HIV infection. AIDS 2000; 14: 1457-8.
36. Little RF, Yarchoan R, Wilson WH. Systemic chemotherapy for HIV-associated lymphoma in the era of highly active antiretroviral therapy. Curr Opin Oncol 2000; 12: 438-44.
37. Gastaldi R, Martino P, Gentile G, Picardi V, De Propris MS, Pirillo MF, et al. Hodgkin's disease in HIV-infected patients: report of eight cases usefully treated with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) plus granulocyte colony-stimulating factor. Ann Oncol 2002; 13: 1158-60.